Thelansis

 Peripheral T-cell lymphoma (PTCL) constitutes a group of uncommon and typically aggressive Non-Hodgkin’s Lymphomas (NHL) arising from mature T-cells. This lymphoma variety originates from mature-stage white blood cells, specifically T-cells and natural killer (NK) cells. It represents a subtype of non-Hodgkin’s Lymphoma (NHL) that predominantly affects T-cells, resulting in abnormal growth and development of these cells. The prognosis for patients with PTCL is generally poor, marked by multiple relapses and initial resistance to treatment. In cases where stem cell transplantation is considered the subsequent therapeutic approach, individuals experiencing relapsed disease are commonly subjected to combined chemotherapy, precisely the ICE regimen (ifosfamide, carboplatin, and etoposide). However, due to the high toxicity levels associated with certain regimens or transplants, they may not be suitable for every patient. Alternatively, less toxic single-agent treatments are available,...